Literature DB >> 34755327

Clinicopathological analysis of retroperitoneal solitary fibrous tumours: a study of 31 cases.

Xiaolu Yuan1, Yuan Liu2, Xuming Wang3, Yu Chen4, Lei Zhang5, Jianguo Wei6.   

Abstract

A solitary fibrous tumour (SFT) is a mesenchymal tumour that exhibits fibroblast differentiation and rarely occurs in the retroperitoneum. The main purpose of this study was to explore the clinical manifestation, histopathological features and biological behaviour of retroperitoneal SFT. From 2011 to 2020, 31 patients were hospitalized and diagnosed with retroperitoneal SFTs. We summarized and analysed the morphological features, immunophenotype, treatment and prognosis. Patients (13 M; 18 F) ranged in age from 25 to 79 years with a mean age of 53.6 years. The main symptoms included an abdominal mass (48.4%) and abdominal discomfort (25.8%). The mean maximum diameter of the tumours was 12.9 cm (range, 4-40 cm). Histopathologically, there were 17 classic cases and 14 hemangiopericytoma-like cases. The tumour cells were positive for STAT6 (96.8%), CD34 (96.8%), CD99 (93.5%) and BCL-2 (90.3%). All patients were treated with complete surgical excision, and 3 of the patients also received chemotherapy. After a median follow up period of 44 months (range, 6 to 107 months), 2 patients died. Patients in the high- or intermediate-risk group were prone to metastasis and/or recurrence. The sites of metastases and/or recurrences involved the liver, bone and pelvis. The Ki-67 labelling index in the high-intermediate risk group (median, 10%) was significantly higher than that in the low-risk group (median, 3%). The retroperitoneal SFT demonstrates an indolent clinical course, and patients from the high- or intermediate-risk group require close follow-up. A Ki-67 labelling index ≥10% may be used as an important reference for prognosis.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34755327     DOI: 10.14670/HH-18-392

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  28 in total

1.  STAT6 is amplified in a subset of dedifferentiated liposarcoma.

Authors:  Leona A Doyle; Derrick Tao; Adrián Mariño-Enríquez
Journal:  Mod Pathol       Date:  2014-01-24       Impact factor: 7.842

2.  Nuclear expression of STAT6 in dedifferentiated liposarcomas with a solitary fibrous tumor-like morphology: a diagnostic pitfall.

Authors:  David Creytens; Louis Libbrecht; Liesbeth Ferdinande
Journal:  Appl Immunohistochem Mol Morphol       Date:  2015-07

3.  Efficacy of bevacizumab and temozolomide therapy in locally advanced, recurrent, and metastatic malignant solitary fibrous tumour: A population-based analysis.

Authors:  Mário L de Lemos; Isabell Kang; Kimberly Schaff
Journal:  J Oncol Pharm Pract       Date:  2018-06-27       Impact factor: 1.809

4.  Superficial Solitary Fibrous Tumor: A Series of 26 Cases.

Authors:  Patrick Feasel; Alyaa Al-Ibraheemi; Karen Fritchie; Riyam T Zreik; Wei-Lien Wang; Elizabeth Demicco; Marcela Saeb-Lima; John R Goldblum; Brian P Rubin; Jesse K McKenney; Jennifer S Ko; Steven D Billings
Journal:  Am J Surg Pathol       Date:  2018-06       Impact factor: 6.394

5.  Solitary fibrous tumour of the pleura.

Authors:  Nicole A Campbell; Phillip N Antippa
Journal:  Heart Lung Circ       Date:  2006-07-03       Impact factor: 2.975

6.  MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.

Authors:  Matthieu Bui Nguyen Binh; Xavier Sastre-Garau; Louis Guillou; Gonzague de Pinieux; Philippe Terrier; Réal Lagacé; Alain Aurias; Isabelle Hostein; Jean Michel Coindre
Journal:  Am J Surg Pathol       Date:  2005-10       Impact factor: 6.394

7.  Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases.

Authors:  D M England; L Hochholzer; M J McCarthy
Journal:  Am J Surg Pathol       Date:  1989-08       Impact factor: 6.394

8.  NAB2-STAT6 gene fusion and STAT6 immunoexpression in extrathoracic solitary fibrous tumors: the association between fusion variants and locations.

Authors:  I-Chieh Chuang; Kuan-Cho Liao; Hsuan-Ying Huang; Yu-Chien Kao; Chien-Feng Li; Shih-Chiang Huang; Jen-Wei Tsai; Ko-Chin Chen; Jui Lan; Po-Chun Lin
Journal:  Pathol Int       Date:  2016-04-04       Impact factor: 2.534

9.  Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics.

Authors:  Leona A Doyle; Marina Vivero; Christopher Dm Fletcher; Fredrik Mertens; Jason L Hornick
Journal:  Mod Pathol       Date:  2013-09-13       Impact factor: 7.842

10.  Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model.

Authors:  Elizabeth G Demicco; Min S Park; Dejka M Araujo; Patricia S Fox; Roland L Bassett; Raphael E Pollock; Alexander J Lazar; Wei-Lien Wang
Journal:  Mod Pathol       Date:  2012-05-11       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.